| NCT ID | NCT07192133 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | University of Wisconsin, Madison |
| Condition | CT Scan |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2026-01-26 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 30 participants in total. It began in 2026-01-26 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to learn if a new computed tomography (CT) lung perfusion imaging method is as effective as standard of care (SOC) CT imaging. The main question it aims to answer is: * Does the new contrast-free method provide more information about lung perfusion than SOC? Participants will undergo a 30 minute chest CT.
Eligibility Criteria
Inclusion Criteria: * Age 18 years or older * Able to sign and date the informed consent form * Will undergo a clinically-indicated CT exam of the head, neck, chest, abdomen, pelvis, or extremities Exclusion Criteria: * Pregnant or lactating * In need of urgent or emergent care * Have any conditions that, in the opinion of the PI or designee, would interfere with the evaluation of the results or constitute a health hazard for the participant
Contact & Investigator
Matthew Smith, MD, PhD
PRINCIPAL INVESTIGATOR
University of Wisconsin, Madison
Frequently Asked Questions
Who can join the NCT07192133 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying CT Scan. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07192133 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07192133 currently recruiting?
Yes, NCT07192133 is actively recruiting participants. Contact the research team at radstudy@uwhealth.org for enrollment information.
Where is the NCT07192133 trial being conducted?
This trial is being conducted at Madison, United States.
Who is sponsoring the NCT07192133 clinical trial?
NCT07192133 is sponsored by University of Wisconsin, Madison. The principal investigator is Matthew Smith, MD, PhD at University of Wisconsin, Madison. The trial plans to enroll 30 participants.